Skip to Main Content
Contribute Try STAT+ Today

In response to Congressional concerns over prescription drug pricing, the Federal Trade Commission released a brief report that suggested the agency is poised to further investigate a controversial contracting practice known as a rebate wall.

The term refers to arrangements between drug makers and pharmacy benefits managers over placement of medicines on formularies, or coverage lists used by health plans. By offering a higher rebate to a PBM for a medicine, but especially for a bundle of medicines, a drug maker can wall off rivals from gaining favorable formulary placement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.